Eindhoven-based Salvia BioElectronics has successfully raised €53 million in a Series B funding round to propel its migraine treatment technology further. Known for its innovative neuromodulation approach, the company aims to provide effective solutions for chronic migraine sufferers. This substantial investment reflects a growing confidence in Salvia BioElectronics, positioning it to make notable advancements in the healthcare technology sector and reach a wider audience of patients in need.
Innovation Industries, which has a history of supporting deep tech companies, led this significant funding round. Previously, the firm was instrumental in backing early-stage ventures focused on addressing critical global challenges. Salvia’s recent achievement echoes its previous financial milestones, strengthening its presence in the competitive medical technology arena.
What Are the Fund Utilisation Plans?
The newly acquired funds will enable Salvia BioElectronics to complete ongoing clinical trials and prepare for the commercial release of MySalvia Therapy. Central to this initiative is the RECLAIM study, aimed at assessing the effectiveness of the therapy on chronic migraine patients. The funds will also support efforts to achieve regulatory approvals from authorities in the United States, Europe, and Australia.
Is Salvia BioElectronics Pioneering Migraine Treatment?
Salvia BioElectronics aims to revolutionize how migraines are treated with its ultra-thin implant technology. This approach offers a minimally invasive and personalized treatment option by targeting critical nerves associated with migraines. Current treatment alternatives often fall short for many patients, marking a demand for new solutions in the field.
Founded in 2017 by Hubert Martens, the company focuses on offering relief to patients who have been unable to find success with existing therapies. MySalvia Therapy introduces a unique feature, allowing patients to activate their treatment through a wearable device. This provides users with the flexibility to manage their symptoms as needed, significantly improving their quality of life.
Salvia BioElectronics’ innovative device is designed to alleviate both migraines and cluster headaches. There is an expectation that the technology will reduce headache frequency and severity, therefore addressing a long-standing issue within the migraine treatment community.
The recent developments mark a turning point for Salvia BioElectronics, encouraging a wider adoption of their technology across different markets. In addition to providing innovative solutions, the organization seeks to profoundly impact chronic migraine sufferers’ lives through lasting and effective treatment options. Moreover, if Salvia’s therapy continues to show promise, it could become a primary choice for millions struggling with these persistent headaches.
